Literature DB >> 30595561

Cyclosporine in Pediatric Nephrology.

Seçil Arslansoyu Camlar1, Alper Soylu, Salih Kavukçu.   

Abstract

Cyclosporine began to be used as one of the immunosuppressive agents in transplantation in the beginning of the 1980s, and in the treatment of nephrotic syndrome in the pediatric nephrology. Therapeutic area of cyclosporine is narrow and its side effects limit its usage. Preference for cyclosporine and tacrolimus as a calcineurin inhibitor is left for the choice of the department. There are still countries with preferred-cyclosporine use because of economic reasons. Cyclosporine is currently being used in the treatment of nephrotic syndrome, but due to its high relapse rates in a short-term use, and nephrotoxicity in long-term use, search for new drugs with fewer side effects keeps continuing. As long as its use is indispensable, it will be necessary to keep track of kidney function and blood level of this medication closely to protect the patients from toxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30595561

Source DB:  PubMed          Journal:  Iran J Kidney Dis        ISSN: 1735-8582            Impact factor:   0.892


  5 in total

1.  Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.

Authors:  Aditi Sinha; Arvind Bagga; Sushmita Banerjee; Kirtisudha Mishra; Amarjeet Mehta; Indira Agarwal; Susan Uthup; Abhijeet Saha; Om Prakash Mishra
Journal:  Indian Pediatr       Date:  2021-03-20       Impact factor: 1.411

2.  Cyclosporine-A-Based Immunosuppressive Therapy-Induced Neurotoxicity: A Case Report.

Authors:  Ali Teimouri; Sayyed Reza Ahmadi; Saeideh Anavri Ardakani; Mahdi Foroughian
Journal:  Open Access Emerg Med       Date:  2020-04-28

Review 3.  Etiology and management of hypertension in patients with cancer.

Authors:  Turab Mohammed; Meghana Singh; John G Tiu; Agnes S Kim
Journal:  Cardiooncology       Date:  2021-04-06

4.  Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.

Authors:  Georgie Mathew; Aditi Sinha; Aijaz Ahmed; Neetu Grewal; Priyanka Khandelwal; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2022-03-14       Impact factor: 3.651

Review 5.  The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.

Authors:  Giuseppe Caruso; Anna Privitera; Barbara Moura Antunes; Giuseppe Lazzarino; Susan Marie Lunte; Giancarlo Aldini; Filippo Caraci
Journal:  Molecules       Date:  2022-07-12       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.